Bio X Cell has recently released a blog post talking about the role of LincRNA EPIC1 in cancer immunology. 

Below are the highlights from the blog post:

The ability of tumour cells to evade immune detection plays a critical role in tumour development.

Although mechanisms of immune evasion have been characterized, understanding of how tumour cells avoid detection by the immune system and acquire resistance to immunotherapy remains incomplete.

Utilizing Bio X Cell’s anti-mouse PD-1 (clone J43) antibody as one of the research tools, researchers discovered that expression of the long intergenic noncoding RNA (lincRNA) EPIC1 helps cancer cells escape recognition by the immune system. These findings establish lincRNAs as biomarkers for predicting clinically relevant immune responses in patients with cancer and reveal EZH2 as a possible therapeutic target in EPIC1 expressing tumours.

Why EPIC1 was selected for further study

A team of scientists led by Dr. Da Yang at the University of Pittsburg began their work by analyzing lincRNA expression in 9,626 human tumour samples spanning 32 tumour types.

 

    • They developed a scoring system called LIMER (lincRNA-based immune response) capable of estimating the extent of immune cell infiltration using RNA sequencing data.
    • High LIMER scores were associated with better progression-free survival in several tumour types including melanoma and liver cancer.
    • The team also found a set of lincRNAs that were exclusively expressed in tumour cells and were negatively correlated with immune response.
    • Among these, EPIC1 was identified as the top scoring lincRNA and was selected for further study.

Scientists sought to explore how lincRNA EPIC1 mediates anti-PD-1 therapy resistance

    • Further characterization of EPIC1 overexpressing tumours revealed the presence of fewer immune cells compared to control tumours.
    • Additionally, a series of experiments in preclinical mouse models revealed that EPIC1 expression results in both suppressions of antigen presentation as well as inhibition of IFN-g–JAK–STAT1 signalling.
    • The researchers found that EPIC1 recruits EZH2, a histone methyltransferase, to chromatin resulting in epigenetic silencing of IFN-g receptor IFNGR1 and genes involved in antigen presentation.
    • Having established that EPIC1 is an important regulator of the immune response, the authors next sought to explore the role of EPIC1 in resistance to anti-PD-1 therapy.

Using Bio X Cell’s in-vivo antibodies in cancer research

    • For this experiment, researchers used a mouse model and Bio X Cell’s anti-mouse PD-1 (clone J43) antibody as one of the research tools to demonstrate that tumours expressing high levels of EPIC1 were resistant to checkpoint inhibition.
    • They also showed that inhibiting EZH2 in EPIC1 expressing cells resulted in restored IFN-g–JAK–STAT1 signalling and MHC-I expression.
    • The results of this work begin to illuminate the role of lincRNAs in cancer biology as well as give clues into potential avenues for therapeutic development.
    • Further exploration of EPIC1 expression in tumour samples could result in its development as a biomarker for resistance to immunotherapy.
    • Additionally, EZH2 inhibitors may represent a rational therapeutic approach in patients with high EPIC1 

Read the full article in Science Advances here.

Reference:

1. LincRNA EPIC1 Mediates Immunotherapy Resistance. BioXCell, 28 Apr. 2021, https://blog.bxcell.com/a-role-for-neutrophilic-inflammation-in-viral-predisposition-0-0

Bio X Cell products are for research use only (RUO) and are NOT FOR THERAPEUTIC USE.

The following Bio X Cell antibodies were featured in this publication:

Bio X Cell products are for research use only (RUO) and are NOT FOR THERAPEUTIC USE.

Contact us for more products on in vivo research.

Share This